Free Trial

Healthcare and Medical Stocks List

This page shows information about the 50 largest healthcare and medical sector stocks including Eli Lilly and Company, Johnson & Johnson, AbbVie and UnitedHealth Group. Learn more about health care stocks.

Eli Lilly and Company stock logo

1. Eli Lilly and Company NYSE:LLY

$984.64 +17.65 (+1.82%)
As of 10:35 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Market Capitalization
$929.57 billion
P/E Ratio
35.06
Consensus Rating
Moderate Buy
Consensus Price Target
$1,218.33 (+23.7% Upside)
Volume
421,639 shares
Average Volume
3.18 million shares
Today's Range
$971.18
$989.00
50-Day Range
$851.65
$1,050.39
52-Week Range
$623.78
$1,133.95
Dividend Yield
0.73%
Johnson & Johnson stock logo

2. Johnson & Johnson NYSE:JNJ

$224.54 +3.11 (+1.41%)
As of 10:35 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. More about Johnson & Johnson

Pros of Johnson & Johnson

  • The current stock price is around $221, which reflects a stable position in the market and potential for growth.
  • Equities researchers have recently increased their FY2027 earnings estimates for Johnson & Johnson, indicating positive future performance expectations.
  • Johnson & Johnson has a strong market capitalization of approximately $533.52 billion, showcasing its significant presence and stability in the healthcare sector.

Cons of Johnson & Johnson

  • Recent pipeline commentary has been mixed, with some programs showing positive progress while others, like a mid-stage inflammatory bowel disease candidate, did not meet key endpoints, creating uncertainty.
  • Despite a strong market position, the company faces ongoing challenges in the healthcare sector, which could impact its growth trajectory.
  • Some analysts have downgraded their ratings, indicating a cautious outlook on the stock's performance in the near term.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$539.95 billion
P/E Ratio
25.93
Consensus Rating
Moderate Buy
Consensus Price Target
$252.48 (+12.4% Upside)
Volume
1.51 million shares
Average Volume
8.36 million shares
Today's Range
$221.65
$224.08
50-Day Range
$221.17
$248.81
52-Week Range
$146.12
$251.71
Dividend Yield
2.35%
AbbVie stock logo

3. AbbVie NYSE:ABBV

$207.36 +4.58 (+2.26%)
As of 10:35 AM Eastern
This is a fair market value price provided by Massive. Learn more.

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. More about AbbVie

Pros of AbbVie

  • AbbVie has received multiple upgrades from analysts, with a consensus target price of approximately $252.90, indicating potential for growth.
  • The current stock price is around $208, which may present a buying opportunity for investors looking for value.
  • AbbVie reported strong quarterly earnings, exceeding expectations with a revenue increase of 12.4% year-over-year, showcasing its robust financial health.

Cons of AbbVie

  • AbbVie has a high price-to-earnings (P/E) ratio, which may indicate that the stock is overvalued compared to its earnings, potentially leading to price corrections.
  • The company has a significant dividend payout ratio, which is over 340%, suggesting that it may be paying out more in dividends than it earns, raising concerns about sustainability.
  • Insider selling activity has been noted, with key executives reducing their holdings, which could signal a lack of confidence in the company's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$366.17 billion
P/E Ratio
102.01
Consensus Rating
Moderate Buy
Consensus Price Target
$252.90 (+22.0% Upside)
Volume
497,655 shares
Average Volume
7.04 million shares
Today's Range
$203.51
$206.64
50-Day Range
$197.24
$235.90
52-Week Range
$176.57
$244.81
Dividend Yield
3.43%
UnitedHealth Group stock logo

4. UnitedHealth Group NYSE:UNH

$384.16 -0.28 (-0.07%)
As of 10:35 AM Eastern
This is a fair market value price provided by Massive. Learn more.

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. More about UnitedHealth Group

Pros of UnitedHealth Group

  • The current stock price is around $379, reflecting a recent increase of 2.6%, which may indicate positive market sentiment.
  • UnitedHealth Group announced the elimination of prior authorization for 30% of healthcare services, potentially streamlining care and improving customer satisfaction, which could enhance profitability.
  • Analysts have raised earnings estimates for FY2027, signaling confidence in the company's long-term profitability and growth potential.

Cons of UnitedHealth Group

  • Despite strong revenue, the company has a net margin of only 2.68%, which may raise concerns about profitability in a competitive market.
  • Recent earnings estimates have been cut by Zacks Research, indicating potential headwinds for the company's near-term performance.
  • The company has a debt-to-equity ratio of 0.69, which, while manageable, suggests a reliance on debt that could pose risks in a rising interest rate environment.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$349.16 billion
P/E Ratio
29.04
Consensus Rating
Moderate Buy
Consensus Price Target
$378.88 (-1.4% Downside)
Volume
1.01 million shares
Average Volume
9.25 million shares
Today's Range
$382.01
$386.49
50-Day Range
$259.15
$384.40
52-Week Range
$234.60
$386.49
Dividend Yield
2.33%
Novartis stock logo

5. Novartis NYSE:NVS

$147.40 +2.17 (+1.50%)
As of 10:35 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. More about Novartis

Pros of Novartis

  • The current stock price is around $149.77, which is relatively stable compared to its 52-week high of $170.46, indicating potential for recovery and growth.
  • Novartis AG has a strong consensus rating of "Hold" from analysts, with several ratings indicating a "Buy," suggesting confidence in the company's future performance.
  • The company reported a solid earnings per share (EPS) of $2.03 recently, surpassing analysts' expectations, which reflects strong operational performance.

Cons of Novartis

  • Recent quarterly revenue showed a slight decline of 0.9% year-over-year, which may raise concerns about the company's growth trajectory.
  • Despite a strong EPS, the company missed analysts' consensus estimates in a recent quarter, which could indicate potential challenges in meeting future expectations.
  • Novartis AG's beta of 0.52 suggests lower volatility compared to the market, but it may also indicate limited growth potential in a rapidly changing industry.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$281.06 billion
P/E Ratio
21.10
Consensus Rating
Hold
Consensus Price Target
$141.20 (-4.2% Downside)
Volume
181,526 shares
Average Volume
2.05 million shares
Today's Range
$145.88
$146.91
50-Day Range
$142.99
$168.61
52-Week Range
$104.93
$170.46
Dividend Yield
2.11%
Merck & Co., Inc. stock logo

6. Merck & Co., Inc. NYSE:MRK

$112.15 +0.87 (+0.78%)
As of 10:35 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. More about Merck & Co., Inc.

Pros of Merck & Co., Inc.

  • Merck's recent acquisition of Terns has strengthened its pipeline for chronic myeloid leukemia (CML), enhancing its position in oncology and potentially leading to significant revenue growth.
  • The current stock price is around $112, reflecting a solid market capitalization of approximately $277 billion, indicating strong investor confidence and stability.
  • Analysts have shown support for Merck after its recent earnings beat, with some raising price targets, suggesting positive sentiment and potential for stock appreciation.

Cons of Merck & Co., Inc.

  • Competitive pressure in key therapeutic areas, particularly oncology and diabetes, has been increasing, as evidenced by strong performances from competitors like Johnson & Johnson and Eli Lilly.
  • Recent profit-taking and relative valuation compression may indicate that the stock is facing challenges in maintaining its current price levels amidst market fluctuations.
  • Mixed analyst views on valuation versus growth suggest uncertainty about Merck's future performance, with some analysts initiating coverage with a neutral rating.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$277.12 billion
P/E Ratio
31.61
Consensus Rating
Moderate Buy
Consensus Price Target
$128.18 (+14.3% Upside)
Volume
866,721 shares
Average Volume
11.00 million shares
Today's Range
$111.39
$112.99
50-Day Range
$109.33
$123.45
52-Week Range
$73.31
$125.14
Dividend Yield
3.05%
Novo Nordisk A/S stock logo

7. Novo Nordisk A/S NYSE:NVO

$46.64 +0.24 (+0.51%)
As of 10:35 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. More about Novo Nordisk A/S

Pros of Novo Nordisk A/S

  • Recent earnings estimates for FY2026 have been increased, indicating positive growth expectations, with analysts forecasting earnings per share of $3.22, slightly up from previous estimates.
  • The current stock price is around $45.78, which may present a buying opportunity for investors looking for growth in the pharmaceutical sector.
  • Strong institutional interest is evident, with significant increases in stakes from major investment firms, suggesting confidence in the company's future performance.

Cons of Novo Nordisk A/S

  • Despite positive earnings forecasts, the consensus estimate for the current full-year earnings is slightly higher at $3.34 per share, indicating potential pressure on meeting or exceeding expectations.
  • Recent downgrades from several brokerages, including a shift from "buy" to "hold" ratings, may signal caution among analysts regarding the stock's short-term performance.
  • The stock has experienced fluctuations, with a 1-year low of $35.12 and a high of $81.44, suggesting volatility that could concern risk-averse investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$208.24 billion
P/E Ratio
10.95
Consensus Rating
Hold
Consensus Price Target
$65.56 (+40.6% Upside)
Volume
4.19 million shares
Average Volume
21.92 million shares
Today's Range
$46.57
$47.11
50-Day Range
$35.28
$46.34
52-Week Range
$35.12
$81.44
Dividend Yield
3.79%
Amgen stock logo

8. Amgen NASDAQ:AMGN

$334.47 +4.88 (+1.48%)
As of 10:35 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. More about Amgen

Pros of Amgen

  • The current stock price is around $329, which reflects a strong market position and potential for growth.
  • Amgen Inc. reported earnings per share of $5.15, exceeding analysts' expectations, indicating robust financial performance.
  • The company has a solid revenue growth of 5.8% compared to the same quarter last year, showcasing its ability to expand its market share.

Cons of Amgen

  • There is investor apprehension regarding Amgen's aggressive strategy in the obesity market, which may impact short-term profits.
  • The company's high debt-to-equity ratio of 5.65 suggests a reliance on debt financing, which can be risky in volatile markets.
  • Recent market commentary has framed the company's quarterly performance as "generally in-line," indicating a lack of significant growth momentum.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$180.42 billion
P/E Ratio
23.26
Consensus Rating
Hold
Consensus Price Target
$357.12 (+6.8% Upside)
Volume
160,234 shares
Average Volume
2.73 million shares
Today's Range
$329.80
$332.92
50-Day Range
$328.91
$388.16
52-Week Range
$261.43
$391.29
Dividend Yield
3.04%
Thermo Fisher Scientific stock logo

9. Thermo Fisher Scientific NYSE:TMO

$459.96 +7.36 (+1.63%)
As of 10:35 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. More about Thermo Fisher Scientific

Pros of Thermo Fisher Scientific

  • The current stock price is around $469, which reflects a strong market position and potential for growth.
  • Recent analyst upgrades indicate positive sentiment, with multiple firms issuing "buy" ratings and setting price targets above the current stock price, suggesting potential upside.
  • The company has a solid market capitalization of approximately $175 billion, indicating stability and investor confidence.

Cons of Thermo Fisher Scientific

  • Recent insider sales, while part of a planned strategy, may raise concerns about executives' confidence in the company's short-term performance.
  • The stock has experienced fluctuations, with a 12-month high of $643.99 and a low of $385.46, indicating volatility that could deter risk-averse investors.
  • Analysts have recently adjusted price targets downward, which may signal a cautious outlook on the company's near-term growth prospects.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$170.99 billion
P/E Ratio
25.30
Consensus Rating
Buy
Consensus Price Target
$619.65 (+34.7% Upside)
Volume
429,985 shares
Average Volume
2.30 million shares
Today's Range
$452.85
$458.78
50-Day Range
$452.14
$531.69
52-Week Range
$385.46
$643.99
Dividend Yield
0.40%
Gilead Sciences stock logo

10. Gilead Sciences NASDAQ:GILD

$134.44 +0.92 (+0.69%)
As of 10:35 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Market Capitalization
$166.59 billion
P/E Ratio
18.28
Consensus Rating
Moderate Buy
Consensus Price Target
$157.04 (+16.8% Upside)
Volume
546,091 shares
Average Volume
6.74 million shares
Today's Range
$132.72
$135.00
50-Day Range
$127.75
$150.03
52-Week Range
$97.86
$157.29
Dividend Yield
2.50%
Intuitive Surgical stock logo

11. Intuitive Surgical NASDAQ:ISRG

$429.93 +9.87 (+2.35%)
As of 10:35 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. More about Intuitive Surgical

Pros of Intuitive Surgical

  • The stock currently has a price around $452, which may present a buying opportunity for investors looking for growth in the medical technology sector.
  • Intuitive Surgical, Inc. has received a consensus rating of "Moderate Buy" from analysts, indicating positive sentiment and potential for price appreciation.
  • The company is a leader in robotic-assisted surgical systems, particularly with its latest da Vinci surgical systems, which enhance precision and control in minimally invasive procedures.

Cons of Intuitive Surgical

  • Recent insider selling activity, including significant sales by executives, may raise concerns about the company's future prospects and insider confidence.
  • Analysts have recently lowered price targets for the stock, indicating a potential decrease in expected growth and profitability.
  • The stock has experienced volatility, with a one-year high of $603.88 and a low of $427.84, suggesting uncertainty in its price stability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$152.24 billion
P/E Ratio
52.11
Consensus Rating
Moderate Buy
Consensus Price Target
$581.91 (+35.4% Upside)
Volume
442,473 shares
Average Volume
2.01 million shares
Today's Range
$420.00
$428.85
50-Day Range
$420.06
$503.51
52-Week Range
$417.74
$603.88
Dividend Yield
N/A
Pfizer stock logo

12. Pfizer NYSE:PFE

$25.88 +0.07 (+0.26%)
As of 10:35 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. More about Pfizer

Pros of Pfizer

  • Pfizer Inc. recently reported strong first-quarter results, indicating robust performance that may attract investors looking for stability and growth.
  • The current stock price is around $28.74, which reflects a positive outlook from analysts, with several raising their price targets, suggesting potential for appreciation.
  • Increased investment in research and development (R&D) could lead to significant breakthroughs in various therapeutic areas, enhancing the company's long-term growth prospects.

Cons of Pfizer

  • Recent guidance from management has been interpreted as conservative, with earnings per share (EPS) and revenue projections sitting at or slightly below consensus, which may dampen investor sentiment.
  • Higher R&D spending has reduced profit margins year-over-year, raising concerns about the company's ability to maintain profitability in the near term.
  • Despite a strong revenue increase, the decline in profit could signal potential challenges in converting R&D investments into successful late-stage products.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$147.58 billion
P/E Ratio
19.77
Consensus Rating
Hold
Consensus Price Target
$28.74 (+11.1% Upside)
Volume
3.92 million shares
Average Volume
42.48 million shares
Today's Range
$25.82
$26.05
50-Day Range
$25.65
$28.56
52-Week Range
$21.97
$28.75
Dividend Yield
6.70%
Abbott Laboratories stock logo

13. Abbott Laboratories NYSE:ABT

$83.73 +1.17 (+1.42%)
As of 10:35 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. More about Abbott Laboratories

Pros of Abbott Laboratories

  • The current stock price is around $115, reflecting a strong market position and investor confidence in the company's growth potential.
  • Abbott Laboratories recently reported quarterly earnings that exceeded analyst expectations, indicating robust financial health and operational efficiency.
  • The company has a solid dividend yield of approximately 2.8%, providing a steady income stream for investors.

Cons of Abbott Laboratories

  • Recent target price reductions by several analysts indicate a cautious outlook, with some lowering their price targets significantly.
  • The company's dividend payout ratio is relatively high at 70.59%, which may raise concerns about sustainability in the long term.
  • Insider trading activity shows a slight decrease in ownership among executives, which could signal a lack of confidence in the company's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$145.89 billion
P/E Ratio
23.46
Consensus Rating
Moderate Buy
Consensus Price Target
$119.43 (+42.6% Upside)
Volume
2.08 million shares
Average Volume
11.76 million shares
Today's Range
$83.09
$84.18
50-Day Range
$82.58
$116.17
52-Week Range
$81.97
$139.06
Dividend Yield
2.99%
Danaher stock logo

14. Danaher NYSE:DHR

$167.68 +1.17 (+0.70%)
As of 10:35 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. More about Danaher

Pros of Danaher

  • The current stock price is around $175, which may present a buying opportunity for investors looking for growth in the healthcare sector.
  • Danaher Co. has a strong institutional ownership, with over 79% of its stock held by institutional investors, indicating confidence in the company's future performance.
  • The company has shown significant growth in recent quarters, with institutional investors like CX Institutional increasing their stake by nearly 4,000% recently, reflecting strong market interest.

Cons of Danaher

  • The stock has experienced volatility, with a 52-week high of $242.80 and a low of $172.34, indicating potential risks associated with price fluctuations.
  • Despite strong institutional backing, insider selling has occurred, with executives like Gregory M. Milosevich reducing their holdings, which may signal concerns about the company's future performance.
  • The price-to-earnings ratio is relatively high at around 33.91, suggesting that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$118.67 billion
P/E Ratio
32.43
Consensus Rating
Moderate Buy
Consensus Price Target
$240.70 (+43.5% Upside)
Volume
520,767 shares
Average Volume
4.29 million shares
Today's Range
$165.57
$167.45
50-Day Range
$166.46
$210.28
52-Week Range
$165.25
$242.80
Dividend Yield
0.93%
CVS Health stock logo

15. CVS Health NYSE:CVS

$92.61 +0.39 (+0.42%)
As of 10:35 AM Eastern
This is a fair market value price provided by Massive. Learn more.

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. More about CVS Health

Pros of CVS Health

  • The stock price has shown potential for growth, with recent analyst upgrades suggesting a target price increase to around $102, indicating a possible upside from its current trading price of approximately $87.70.
  • CVS Health Co. has received multiple "buy" ratings from various analysts, reflecting strong confidence in its future performance and stability in the healthcare sector.
  • The company is actively investing in technology, such as its recent strategic investment in Fathom, which aims to enhance efficiency through autonomous coding, potentially reducing administrative costs.

Cons of CVS Health

  • Concerns have been raised regarding CVS Health Co.'s affiliation with Mass General Brigham, which may complicate execution and investor sentiment due to potential regulatory scrutiny.
  • There are ongoing challenges in the retail pharmacy sector, with reports of competitors closing stores, indicating tough market conditions that could impact CVS Health Co.'s performance.
  • Despite positive ratings, some analysts have adjusted their price targets downward, reflecting cautious sentiment about the company's near-term growth prospects.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$118.30 billion
P/E Ratio
40.85
Consensus Rating
Moderate Buy
Consensus Price Target
$97.00 (+4.7% Upside)
Volume
1.78 million shares
Average Volume
8.51 million shares
Today's Range
$91.50
$92.68
50-Day Range
$69.98
$92.22
52-Week Range
$58.35
$92.77
Dividend Yield
2.94%
Bristol Myers Squibb stock logo

16. Bristol Myers Squibb NYSE:BMY

$56.18 +0.52 (+0.93%)
As of 10:35 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. More about Bristol Myers Squibb

Pros of Bristol Myers Squibb

  • The current stock price is around $58, which may present a buying opportunity for investors looking for value in the biopharmaceutical sector.
  • Bristol-Myers Squibb has a strong portfolio of products, including recent advancements in oncology treatments like Opdualag for melanoma, which could drive future revenue growth.
  • The company reported a revenue increase of 2.6% compared to the same quarter last year, indicating a positive trend in sales performance.

Cons of Bristol Myers Squibb

  • Analysts have maintained a Hold rating, suggesting uncertainty about the company's ability to offset declines from legacy products.
  • The company faces challenges with the upcoming patent expiration of Eliquis, which could significantly impact revenue streams.
  • Despite recent revenue growth, the overall market sentiment remains cautious, which may affect stock performance in the near term.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$114.55 billion
P/E Ratio
15.76
Consensus Rating
Hold
Consensus Price Target
$61.31 (+9.1% Upside)
Volume
977,264 shares
Average Volume
12.33 million shares
Today's Range
$55.45
$56.31
50-Day Range
$55.62
$62.39
52-Week Range
$42.52
$62.89
Dividend Yield
4.49%
Vertex Pharmaceuticals stock logo

17. Vertex Pharmaceuticals NASDAQ:VRTX

$448.62 +13.45 (+3.09%)
As of 10:35 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). More about Vertex Pharmaceuticals

Pros of Vertex Pharmaceuticals

  • The current stock price is around $427.65, which may present a buying opportunity for investors looking for growth in the biotechnology sector.
  • Vertex Pharmaceuticals Incorporated has recently reported strong quarterly earnings, exceeding analysts' expectations with an EPS of $4.47, indicating robust financial health and operational efficiency.
  • Analysts have a consensus rating of "Moderate Buy" for Vertex Pharmaceuticals Incorporated, with multiple firms raising their price targets, suggesting positive market sentiment and potential for stock appreciation.

Cons of Vertex Pharmaceuticals

  • Insider selling has been observed, with corporate insiders selling over 80,000 shares valued at approximately $37.9 million in the last 90 days, which may raise concerns about the company's future prospects.
  • Despite strong earnings, the stock has experienced fluctuations, and the current price is significantly lower than its 52-week high of $507.92, indicating potential volatility.
  • Analysts have mixed ratings, with some firms downgrading their outlook, which could signal uncertainty about the company's future performance in a competitive market.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$113.60 billion
P/E Ratio
26.55
Consensus Rating
Moderate Buy
Consensus Price Target
$555.17 (+23.8% Upside)
Volume
121,221 shares
Average Volume
1.37 million shares
Today's Range
$436.48
$445.61
50-Day Range
$423.24
$499.17
52-Week Range
$362.50
$507.92
Dividend Yield
N/A
Stryker stock logo

18. Stryker NYSE:SYK

$289.96 +7.38 (+2.61%)
As of 10:35 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. More about Stryker

Pros of Stryker

  • The current stock price is around $292, which may present a buying opportunity for investors looking for value in the medical technology sector.
  • Stryker Co. has received multiple "overweight" ratings from analysts, indicating strong confidence in its future performance.
  • The company reported a revenue increase of 2.6% compared to the same quarter last year, showcasing its ability to grow even in challenging market conditions.

Cons of Stryker

  • The company recently missed earnings expectations, reporting $2.60 earnings per share, which was below the consensus estimate of $2.98, raising concerns about its short-term performance.
  • Analysts have adjusted their price targets downward, with UBS Group lowering its target from $400 to $380, indicating a more cautious outlook.
  • Insider selling activity has been noted, with a director selling a significant number of shares, which could signal a lack of confidence in the stock's near-term prospects.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$111.04 billion
P/E Ratio
33.56
Consensus Rating
Moderate Buy
Consensus Price Target
$395.48 (+36.4% Upside)
Volume
228,988 shares
Average Volume
2.12 million shares
Today's Range
$284.75
$289.04
50-Day Range
$282.85
$387.53
52-Week Range
$281.00
$404.87
Dividend Yield
1.23%
Sanofi stock logo

19. Sanofi NASDAQ:SNY

$42.83 +0.33 (+0.78%)
As of 10:35 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. More about Sanofi

Pros of Sanofi

  • Sanofi has recently increased its annual dividend to $2.4225, reflecting a strong commitment to returning value to shareholders, which can be attractive for income-focused investors.
  • The current stock price is around $44.55, which may present a buying opportunity for investors looking for value in the pharmaceutical sector.
  • Analysts have issued a consensus target price of $62.67, suggesting potential upside for investors if the stock approaches this target.

Cons of Sanofi

  • Recent earnings estimates for FY2026 have been reduced to $4.92 per share, indicating potential challenges in meeting previous growth expectations.
  • Sanofi's stock has experienced fluctuations, with a 1-year low of $44.00, which may raise concerns about its stability and performance in the market.
  • Several analysts have downgraded their ratings on Sanofi, with a notable shift from "strong-buy" to "buy," suggesting a more cautious outlook on the stock's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$104.44 billion
P/E Ratio
11.96
Consensus Rating
Hold
Consensus Price Target
$51.00 (+19.1% Upside)
Volume
540,776 shares
Average Volume
3.71 million shares
Today's Range
$42.56
$42.85
50-Day Range
$42.50
$48.66
52-Week Range
$42.44
$53.36
Dividend Yield
4.09%
GSK stock logo

20. GSK NYSE:GSK

$50.86 +1.05 (+2.11%)
As of 10:35 AM Eastern
This is a fair market value price provided by Massive. Learn more.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. More about GSK

Pros of GSK

  • GSK plc is currently recognized as a momentum stock, attracting interest from long-term investors, which can lead to potential stock price appreciation.
  • The company recently announced a quarterly dividend of $0.44 per share, providing a yield of approximately 3.4%, which can be appealing for income-focused investors.
  • GSK plc's revenue has shown a year-over-year increase, indicating strong operational performance and growth potential in its pharmaceutical and healthcare segments.

Cons of GSK

  • GSK plc recently withdrew its application for leucovorin calcium, which could negatively impact investor sentiment and limit potential revenue from this product.
  • There has been a significant increase in short interest, indicating a rise in bearish sentiment among investors, which can lead to increased volatility in the stock price.
  • Market commentary suggests mixed views on GSK plc's valuation after a strong run, leading some investors to reassess the risk versus reward of holding the stock.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$103.29 billion
P/E Ratio
13.23
Consensus Rating
Reduce
Consensus Price Target
$53.00 (+4.2% Upside)
Volume
794,371 shares
Average Volume
5.06 million shares
Today's Range
$50.34
$50.87
50-Day Range
$49.82
$59.19
52-Week Range
$35.45
$61.69
Dividend Yield
3.73%
Medtronic stock logo

21. Medtronic NYSE:MDT

$75.65 +1.11 (+1.49%)
As of 10:35 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. More about Medtronic

Pros of Medtronic

  • The stock has a consensus target price of approximately $107.80, indicating potential for price appreciation from its current trading levels.
  • Medtronic plc has a strong market capitalization of over $105 billion, reflecting its significant presence and stability in the medical technology sector.
  • Recent analyst ratings show a mix of "buy" and "hold" recommendations, suggesting confidence in the company's future performance.

Cons of Medtronic

  • Insider ownership is relatively low at 0.26%, which may raise concerns about alignment between management and shareholder interests.
  • Recent stock performance has shown volatility, with the price fluctuating between a 52-week low of around $79.93 and a high of approximately $106.33.
  • Some analysts have downgraded their ratings, indicating potential caution regarding the company's short-term outlook.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$97.19 billion
P/E Ratio
21.09
Consensus Rating
Moderate Buy
Consensus Price Target
$107.80 (+42.5% Upside)
Volume
1.47 million shares
Average Volume
8.59 million shares
Today's Range
$74.60
$75.46
50-Day Range
$74.56
$98.09
52-Week Range
$74.40
$106.33
Dividend Yield
3.73%
HCA Healthcare stock logo

22. HCA Healthcare NYSE:HCA

$429.02 +2.65 (+0.62%)
As of 10:35 AM Eastern
This is a fair market value price provided by Massive. Learn more.

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. More about HCA Healthcare

Pros of HCA Healthcare

  • The current stock price is around $430, which may present a buying opportunity for investors looking for value in the healthcare sector.
  • HCA Healthcare, Inc. has shown resilience with a quarterly revenue increase of 4.3% year-over-year, indicating strong operational performance.
  • The company recently announced a quarterly dividend of $0.78, reflecting a commitment to returning value to shareholders, with an annualized yield of 0.7%.

Cons of HCA Healthcare

  • The company experienced a negative return on equity of 295.93%, which may raise concerns about its profitability and efficiency in generating returns for shareholders.
  • Recent insider selling, with executives offloading shares, could signal a lack of confidence in the company's near-term performance.
  • The lapse in ACA subsidy funding has negatively impacted recent results, costing the company approximately $150 million in Q1, which could affect future earnings.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$95.18 billion
P/E Ratio
14.75
Consensus Rating
Moderate Buy
Consensus Price Target
$517.82 (+20.7% Upside)
Volume
154,796 shares
Average Volume
1.11 million shares
Today's Range
$424.83
$432.79
50-Day Range
$426.58
$545.88
52-Week Range
$330.00
$556.52
Dividend Yield
0.72%
McKesson stock logo

23. McKesson NYSE:MCK

$728.04 +2.87 (+0.40%)
As of 10:35 AM Eastern
This is a fair market value price provided by Massive. Learn more.

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. More about McKesson

Pros of McKesson

  • The current stock price is around $815, which reflects a strong market position and potential for growth.
  • McKesson Co. has received multiple "buy" ratings from analysts, indicating confidence in its future performance.
  • The company reported a significant revenue increase of 11.4% compared to the same quarter last year, showcasing its robust business model.

Cons of McKesson

  • The stock has experienced fluctuations, with a one-year high of $999 and a low of $637, indicating potential volatility.
  • McKesson Co. has a negative return on equity, which may raise concerns about its profitability and efficiency in generating returns for shareholders.
  • Recent insider selling activity could signal a lack of confidence from executives regarding the company's short-term prospects.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$89.15 billion
P/E Ratio
18.92
Consensus Rating
Moderate Buy
Consensus Price Target
$963.20 (+32.3% Upside)
Volume
92,481 shares
Average Volume
819,929 shares
Today's Range
$725.20
$734.32
50-Day Range
$724.87
$995.05
52-Week Range
$637.00
$999.00
Dividend Yield
0.45%
Elevance Health stock logo

24. Elevance Health NYSE:ELV

$379.80 -1.95 (-0.51%)
As of 10:35 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. The company operates in the pharmacy services business; and markets and offers pharmacy services, including pharmacy benefit management, as well as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services. In addition, it provides healthcare-related services and capabilities, including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services, subrogation services, and health and wellness programs, as well as services related to data management, information technology, and business operations. Further, the company is involved in the National Government Services business. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brand names. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.

Market Capitalization
$82.58 billion
P/E Ratio
16.18
Consensus Rating
Moderate Buy
Consensus Price Target
$384.58 (+1.3% Upside)
Volume
317,164 shares
Average Volume
1.83 million shares
Today's Range
$375.31
$382.45
50-Day Range
$280.80
$381.58
52-Week Range
$273.71
$412.96
Dividend Yield
1.82%
Boston Scientific stock logo

25. Boston Scientific NYSE:BSX

$54.02 +0.65 (+1.23%)
As of 10:35 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. More about Boston Scientific

Pros of Boston Scientific

  • The company has received strong support for its executive compensation plans, with over 90% of shares voting in favor, indicating investor confidence in management's performance.
  • Boston Scientific Co. has a robust portfolio of products used in less-invasive medical procedures, which is a growing market segment, enhancing its potential for future revenue growth.
  • The current stock price is around $93.49, reflecting a significant transaction by the CEO, which may indicate confidence in the company's future performance.

Cons of Boston Scientific

  • There are ongoing securities fraud class action lawsuits alleging misleading statements about the company's growth, which could lead to financial liabilities and affect stock performance.
  • Recent stockholder proposals for enhanced shareholder rights did not pass, indicating potential dissatisfaction among some investors regarding governance issues.
  • The company has faced significant litigation related to pelvic health mesh products, which could result in costly settlements and impact financial stability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$80.27 billion
P/E Ratio
22.60
Consensus Rating
Moderate Buy
Consensus Price Target
$93.91 (+73.8% Upside)
Volume
1.82 million shares
Average Volume
16.46 million shares
Today's Range
$53.49
$54.15
50-Day Range
$53.33
$76.68
52-Week Range
$53.15
$109.50
Dividend Yield
N/A
Cigna Group stock logo

26. Cigna Group NYSE:CI

$289.90 +0.83 (+0.29%)
As of 10:35 AM Eastern
This is a fair market value price provided by Massive. Learn more.

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. More about Cigna Group

Pros of Cigna Group

  • Analyst sentiment remains largely positive, with multiple buy ratings and a median price target around $334, suggesting potential upside from current levels if the company continues to execute effectively.
  • The Cigna Group's recent earnings report showed a strong performance from its Evernorth unit, which supports durable service-fee revenue, indicating a solid foundation for future growth.
  • The current stock price is approximately $288, which may be seen as an attractive entry point for investors looking for value in the healthcare sector.

Cons of Cigna Group

  • The Cigna Group's decision to exit the Affordable Care Act individual market in 2027 could impact approximately 369,000 members, reducing future premium revenue and potentially alarming investors focused on top-line growth.
  • There are ongoing pressures related to pharmacy benefit management costs, with higher drug prices posing a risk to profit margins if not effectively managed through pricing strategies or cost controls.
  • Recent insider trading activity, including significant stock sales by company insiders, may raise concerns about the confidence of those closest to the company regarding its future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$76.67 billion
P/E Ratio
12.29
Consensus Rating
Moderate Buy
Consensus Price Target
$338.35 (+16.7% Upside)
Volume
291,504 shares
Average Volume
1.68 million shares
Today's Range
$286.43
$290.86
50-Day Range
$257.97
$292.16
52-Week Range
$239.51
$338.89
Dividend Yield
2.17%
Regeneron Pharmaceuticals stock logo

27. Regeneron Pharmaceuticals NASDAQ:REGN

$719.04 +6.27 (+0.88%)
As of 10:35 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. More about Regeneron Pharmaceuticals

Pros of Regeneron Pharmaceuticals

  • The current stock price is around $701, which may present a buying opportunity for investors looking for value in the biotechnology sector.
  • Regeneron Pharmaceuticals, Inc. recently reported a quarterly revenue increase of approximately 19% year-over-year, indicating strong growth potential.
  • The company has a solid market capitalization of around $74 billion, reflecting its stability and established presence in the biopharmaceutical industry.

Cons of Regeneron Pharmaceuticals

  • Despite the revenue growth, net income has fallen, highlighting potential margin pressures and expense management challenges that could affect profitability.
  • Recent U.S. sales of high-dose Eylea have missed expectations, raising concerns about future revenue from this key product and increasing competition in the market.
  • Market reactions have been negative, with the stock experiencing downward pressure as analysts have trimmed forecasts and price targets following earnings reports.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$75.68 billion
P/E Ratio
17.44
Consensus Rating
Moderate Buy
Consensus Price Target
$826.59 (+15.0% Upside)
Volume
82,255 shares
Average Volume
743,070 shares
Today's Range
$710.02
$718.89
50-Day Range
$686.36
$790.81
52-Week Range
$476.49
$821.11
Dividend Yield
0.53%
Takeda Pharmaceutical stock logo

28. Takeda Pharmaceutical NYSE:TAK

$16.44 +0.09 (+0.52%)
As of 10:34 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. More about Takeda Pharmaceutical

Pros of Takeda Pharmaceutical

  • Takeda Pharmaceutical Company Limited has recently been upgraded to a "strong-buy" rating, indicating strong confidence from analysts in the company's future performance.
  • The current stock price is around $16.74, which is near its fifty-two week high of $18.90, suggesting potential for further growth.
  • The company has a solid market capitalization of approximately $53 billion, reflecting its significant presence in the biopharmaceutical industry.

Cons of Takeda Pharmaceutical

  • The company reported earnings that missed consensus estimates, which may raise concerns about its ability to meet financial expectations.
  • Takeda has a relatively high P/E ratio, indicating that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
  • Despite a strong market presence, the company has a net margin of only 2.58%, suggesting limited profitability that could impact future growth.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$52.37 billion
P/E Ratio
68.57
Consensus Rating
Moderate Buy
Consensus Price Target
N/A
Volume
531,768 shares
Average Volume
2.96 million shares
Today's Range
$16.34
$16.46
50-Day Range
$16.31
$18.77
52-Week Range
$12.99
$18.90
Dividend Yield
3.06%
Cencora stock logo

29. Cencora NYSE:COR

$261.67 +1.97 (+0.76%)
As of 10:35 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. More about Cencora

Pros of Cencora

  • The current stock price is around $398, reflecting a strong market position and investor confidence.
  • Cencora, Inc. has recently received multiple upgrades from analysts, indicating positive growth expectations and a consensus rating of "Moderate Buy."
  • The company reported a year-over-year revenue increase of 5.5%, showcasing its ability to grow despite market challenges.

Cons of Cencora

  • The company has a relatively high debt-to-equity ratio of 3.62, which may indicate financial risk and reliance on borrowed funds.
  • Despite a positive earnings report, Cencora, Inc. fell short of revenue expectations, which could raise concerns about future performance.
  • The stock has shown volatility, with a beta of 0.72, suggesting it may not be as stable as some investors prefer.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$50.90 billion
P/E Ratio
20.06
Consensus Rating
Moderate Buy
Consensus Price Target
$380.25 (+45.3% Upside)
Volume
226,791 shares
Average Volume
1.46 million shares
Today's Range
$259.07
$263.03
50-Day Range
$253.20
$372.90
52-Week Range
$244.82
$377.54
Dividend Yield
0.92%
argenex stock logo

30. argenex NASDAQ:ARGX

$815.17 +1.89 (+0.23%)
As of 10:35 AM Eastern
This is a fair market value price provided by Massive. Learn more.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. More about argenex

Pros of argenex

  • The current stock price is around $805, reflecting strong market interest and confidence in the company's growth potential.
  • argenx SE has a robust pipeline of therapies targeting severe autoimmune diseases, with its lead product candidate, efgartigimod, showing promising results in clinical trials.
  • The company has established strategic partnerships with major firms like AbbVie and Zai Lab, which can enhance its research capabilities and market reach.

Cons of argenex

  • The stock has experienced volatility, with a 1-year high of $934.62 and a low of $510.05, indicating potential risks associated with price fluctuations.
  • Despite strong growth prospects, the company operates in a highly competitive biotechnology sector, which may impact its market share and profitability.
  • High valuation metrics, such as a price-to-earnings ratio above 40, may suggest that the stock is overvalued compared to its earnings potential.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$50.54 billion
P/E Ratio
36.18
Consensus Rating
Moderate Buy
Consensus Price Target
$1,017.78 (+24.9% Upside)
Volume
90,323 shares
Average Volume
359,280 shares
Today's Range
$806.67
$818.19
50-Day Range
$663.93
$849.04
52-Week Range
$510.05
$934.62
Dividend Yield
N/A
Edwards Lifesciences stock logo

31. Edwards Lifesciences NYSE:EW

$79.15 +1.98 (+2.56%)
As of 10:35 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. More about Edwards Lifesciences

Pros of Edwards Lifesciences

  • The current stock price is around $82, which reflects a stable position in the market.
  • Edwards Lifesciences Co. reported a significant revenue increase of 16.7% compared to the same quarter last year, indicating strong growth potential.
  • The company has a solid net margin of 17.39%, showcasing effective cost management and profitability.

Cons of Edwards Lifesciences

  • The price-to-earnings (PE) ratio of 44.72 suggests that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
  • Insider selling activity has been notable, with corporate insiders selling a total of 88,096 shares recently, which may signal a lack of confidence in the stock's short-term performance.
  • The company's beta of 0.87 indicates lower volatility compared to the market, which might not appeal to investors seeking high-risk, high-reward opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$45.61 billion
P/E Ratio
42.13
Consensus Rating
Moderate Buy
Consensus Price Target
$95.65 (+20.9% Upside)
Volume
894,495 shares
Average Volume
4.76 million shares
Today's Range
$77.35
$79.33
50-Day Range
$77.11
$87.27
52-Week Range
$72.30
$87.89
Dividend Yield
N/A
Cardinal Health stock logo

32. Cardinal Health NYSE:CAH

$183.14 +0.64 (+0.35%)
As of 10:35 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Cardinal Health, Inc operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. More about Cardinal Health

Pros of Cardinal Health

  • Analysts maintain a generally positive outlook, with several firms recently raising their price targets, indicating confidence in the company's future performance.
  • The current stock price is around $245, reflecting a stable position in the market despite recent fluctuations.
  • Cardinal Health, Inc. has reported strong earnings per share (EPS) performance, which can signal profitability and operational efficiency to investors.

Cons of Cardinal Health

  • Recent revenue figures missed expectations, which can lead to short-term selling pressure and indicate potential challenges in meeting market demands.
  • GAAP results showed a decline in operating earnings and EPS, primarily due to a significant goodwill impairment charge, which can raise concerns about the company's financial health.
  • The mixed nature of recent financial reports, with strong EPS but weak revenue, may create uncertainty and volatility, potentially deterring some investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$42.92 billion
P/E Ratio
28.02
Consensus Rating
Moderate Buy
Consensus Price Target
$241.80 (+32.0% Upside)
Volume
227,857 shares
Average Volume
1.81 million shares
Today's Range
$181.75
$184.00
50-Day Range
$182.63
$230.12
52-Week Range
$137.75
$233.60
Dividend Yield
1.11%
IDEXX Laboratories stock logo

33. IDEXX Laboratories NASDAQ:IDXX

$539.98 +7.98 (+1.50%)
As of 10:35 AM Eastern
This is a fair market value price provided by Massive. Learn more.

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. More about IDEXX Laboratories

Pros of IDEXX Laboratories

  • The current stock price is around $560, which may present a buying opportunity for investors looking for growth in the veterinary diagnostics sector.
  • Seven analysts have rated the stock with a Buy rating, indicating strong confidence in the company's future performance.
  • IDEXX Laboratories, Inc. has a solid market capitalization of approximately $44.54 billion, reflecting its strong position in the industry.

Cons of IDEXX Laboratories

  • The stock has seen a decrease in price targets from various analysts, with recent adjustments lowering expectations for future performance.
  • Insider sales have totaled over $29 million in the last three months, which could raise concerns about the company's short-term outlook.
  • The stock has a relatively high P/E ratio of around 42.91, which may suggest that it is overvalued compared to its earnings.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$42.63 billion
P/E Ratio
39.80
Consensus Rating
Moderate Buy
Consensus Price Target
$751.00 (+39.1% Upside)
Volume
63,658 shares
Average Volume
528,148 shares
Today's Range
$534.24
$542.98
50-Day Range
$532.00
$656.73
52-Week Range
$496.61
$769.98
Dividend Yield
N/A
Haleon stock logo

34. Haleon NYSE:HLN

$9.12 +0.14 (+1.50%)
As of 10:34 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. More about Haleon

Pros of Haleon

  • The current stock price is around $9.59, which may present a buying opportunity for investors looking for value in the consumer healthcare sector.
  • Haleon plc has a strong consensus rating of "Moderate Buy" from analysts, indicating positive sentiment and potential for price appreciation.
  • The company recently reported a significant revenue of $3.65 billion, showcasing its robust market presence and operational strength.

Cons of Haleon

  • Deutsche Bank recently downgraded Haleon from a "hold" to a "sell" rating, which may indicate concerns about the company's short-term performance.
  • The stock has experienced fluctuations, with a 12-month high of $11.42 and a low of $8.71, suggesting volatility that could deter risk-averse investors.
  • Haleon's current ratio of 0.92 indicates that the company may have liquidity challenges, as it has less current assets than current liabilities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$40.51 billion
P/E Ratio
23.35
Consensus Rating
Moderate Buy
Consensus Price Target
$13.40 (+47.0% Upside)
Volume
1.55 million shares
Average Volume
8.50 million shares
Today's Range
$9.04
$9.12
50-Day Range
$8.98
$11.06
52-Week Range
$8.71
$11.42
Dividend Yield
2.66%
Teva Pharmaceutical Industries stock logo

35. Teva Pharmaceutical Industries NYSE:TEVA

$35.13 -0.71 (-1.99%)
As of 10:35 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Market Capitalization
$40.49 billion
P/E Ratio
26.48
Consensus Rating
Moderate Buy
Consensus Price Target
$41.78 (+18.9% Upside)
Volume
974,618 shares
Average Volume
8.17 million shares
Today's Range
$34.91
$35.60
50-Day Range
$28.37
$36.36
52-Week Range
$14.99
$37.35
Dividend Yield
N/A
Becton, Dickinson and Company stock logo

36. Becton, Dickinson and Company NYSE:BDX

$145.19 +2.04 (+1.43%)
As of 10:35 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. More about Becton, Dickinson and Company

Pros of Becton, Dickinson and Company

  • The current stock price is around $149, which may present a buying opportunity for investors looking for value in the medical technology sector.
  • Becton, Dickinson and Company has a strong history of dividend payments, with a recent quarterly dividend of $1.05 per share, translating to an annualized dividend yield of 2.8%. This can provide a steady income stream for investors.
  • The company reported earnings per share of $2.91, exceeding analysts' expectations, indicating strong financial performance and potential for future growth.

Cons of Becton, Dickinson and Company

  • The company’s revenue for the latest quarter was $4.49 billion, which fell short of analysts' expectations, suggesting potential challenges in meeting future growth targets.
  • With a debt-to-equity ratio of 0.67, while manageable, it indicates that the company has a moderate level of debt, which could pose risks in a rising interest rate environment.
  • The stock has experienced volatility, with a one-year high of $187.35 and a low of $127.59, which may concern risk-averse investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$40.03 billion
P/E Ratio
36.78
Consensus Rating
Hold
Consensus Price Target
$184.86 (+27.3% Upside)
Volume
347,486 shares
Average Volume
2.83 million shares
Today's Range
$144.51
$146.90
50-Day Range
$143.11
$176.68
52-Week Range
$127.59
$187.35
Dividend Yield
2.81%
Alnylam Pharmaceuticals stock logo

37. Alnylam Pharmaceuticals NASDAQ:ALNY

$295.61 +10.77 (+3.78%)
As of 10:35 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. More about Alnylam Pharmaceuticals

Pros of Alnylam Pharmaceuticals

  • The stock has shown resilience with a current price around $308, indicating potential for recovery and growth in the biotech sector.
  • Analysts have a consensus rating of "Moderate Buy" with a target price averaging around $472.78, suggesting significant upside potential.
  • Recent insider transactions indicate confidence in the company, with executives selling shares primarily for tax obligations rather than lack of faith in the company's future.

Cons of Alnylam Pharmaceuticals

  • The stock has experienced volatility, with a 12-month high of $495.55 and a low of $240.00, indicating potential risks associated with price fluctuations.
  • Insider ownership is relatively low at around 0.86%, which may suggest a lack of alignment between management and shareholder interests.
  • Recent analyst downgrades have occurred, with some firms reducing their price targets significantly, reflecting concerns about future growth prospects.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$39.40 billion
P/E Ratio
80.63
Consensus Rating
Moderate Buy
Consensus Price Target
$471.96 (+59.7% Upside)
Volume
77,874 shares
Average Volume
1.29 million shares
Today's Range
$286.73
$294.52
50-Day Range
$284.84
$339.41
52-Week Range
$261.45
$495.55
Dividend Yield
N/A
BeOne Medicines stock logo

38. BeOne Medicines NASDAQ:ONC

$313.76 +3.01 (+0.97%)
As of 10:35 AM Eastern
This is a fair market value price provided by Massive. Learn more.

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Market Capitalization
$34.44 billion
P/E Ratio
70.23
Consensus Rating
Moderate Buy
Consensus Price Target
$391.00 (+24.6% Upside)
Volume
104,717 shares
Average Volume
253,404 shares
Today's Range
$313.84
$319.00
50-Day Range
$274.73
$323.87
52-Week Range
$218.31
$385.22
Dividend Yield
N/A
Waters stock logo

39. Waters NYSE:WAT

$346.74 -1.33 (-0.38%)
As of 10:35 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. In addition, the company offers MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. Further, the company provides thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by clinical, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company was founded in 1958 and is headquartered in Milford, Massachusetts.

Market Capitalization
$34.03 billion
P/E Ratio
44.04
Consensus Rating
Moderate Buy
Consensus Price Target
$395.12 (+14.0% Upside)
Volume
166,192 shares
Average Volume
1.08 million shares
Today's Range
$342.70
$349.95
50-Day Range
$283.58
$355.12
52-Week Range
$275.05
$414.15
Dividend Yield
N/A
Humana stock logo

40. Humana NYSE:HUM

$279.88 +5.62 (+2.05%)
As of 10:35 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. More about Humana

Pros of Humana

  • Humana Inc. recently reported earnings per share (EPS) of $10.31, exceeding analysts' expectations, which indicates strong financial performance and potential for growth.
  • The company has shown significant revenue growth, with a 23.5% increase compared to the same quarter last year, suggesting robust demand for its services.
  • Humana Inc. has a current stock price around $235, which reflects a potential upside based on recent analyst price targets, indicating a favorable investment opportunity.

Cons of Humana

  • Despite recent growth, Humana Inc. has faced downgrades from some analysts, indicating potential concerns about future performance.
  • The company has a relatively low net margin of 0.82%, which may raise questions about its profitability compared to competitors.
  • Some analysts have set price targets significantly lower than the current stock price, suggesting that the stock may be overvalued at this time.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$33.59 billion
P/E Ratio
29.92
Consensus Rating
Hold
Consensus Price Target
$247.61 (-11.5% Downside)
Volume
167,514 shares
Average Volume
1.97 million shares
Today's Range
$271.96
$278.70
50-Day Range
$163.80
$274.58
52-Week Range
$163.11
$315.35
Dividend Yield
1.29%
Zoetis stock logo

41. Zoetis NYSE:ZTS

$76.69 +0.02 (+0.02%)
As of 10:35 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. More about Zoetis

Pros of Zoetis

  • The current stock price is around $112.60, which may present a buying opportunity for investors looking for value in the market.
  • Zoetis Inc. has shown resilience with a net margin of over 28%, indicating strong profitability and effective cost management.
  • The company reported a year-over-year revenue increase of 3.0%, suggesting growth potential in its operations.

Cons of Zoetis

  • Recent trading has been affected by negative headlines and a guidance cut, leading to a sharp drop in share price.
  • Brokerage reports have downgraded ratings, with some analysts moving from "buy" to "hold," indicating caution among market experts.
  • The company has a relatively high debt-to-equity ratio of 2.71, which may raise concerns about financial leverage and risk.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$32.15 billion
P/E Ratio
12.72
Consensus Rating
Hold
Consensus Price Target
$141.25 (+84.2% Upside)
Volume
2.06 million shares
Average Volume
4.69 million shares
Today's Range
$76.35
$78.09
50-Day Range
$76.62
$131.06
52-Week Range
$76.35
$172.23
Dividend Yield
2.56%
Agilent Technologies stock logo

42. Agilent Technologies NYSE:A

$112.09 +0.63 (+0.57%)
As of 10:35 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. More about Agilent Technologies

Pros of Agilent Technologies

  • The current stock price is around $114.84, which may present a buying opportunity for investors looking for growth in the scientific instrumentation sector.
  • Agilent Technologies, Inc. reported a revenue increase of 7.0% compared to the same quarter last year, indicating strong business performance and potential for future growth.
  • The company has a solid return on equity of 24.49%, suggesting effective management and profitability, which can be attractive to investors seeking reliable returns.

Cons of Agilent Technologies

  • The company recently missed earnings estimates, reporting $1.36 EPS compared to the consensus estimate of $1.37, which may raise concerns about its short-term performance.
  • Agilent Technologies, Inc. has seen its stock price decline from a 12-month high of $160.27, which could indicate a downward trend that investors should be cautious of.
  • With a P/E ratio of 25.35, the stock may be considered overvalued compared to its earnings, which could deter value-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$31.74 billion
P/E Ratio
24.79
Consensus Rating
Buy
Consensus Price Target
$163.71 (+46.1% Upside)
Volume
156,126 shares
Average Volume
2.16 million shares
Today's Range
$111.09
$112.57
50-Day Range
$110.35
$122.10
52-Week Range
$107.07
$160.27
Dividend Yield
0.88%
Alcon stock logo

43. Alcon NYSE:ALC

$63.44 +1.42 (+2.29%)
As of 10:35 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Alcon Inc researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. More about Alcon

Pros of Alcon

  • Recent analyst ratings have been positive, with multiple firms issuing buy ratings, indicating strong confidence in the company's future performance.
  • The median price target set by analysts for Alcon Inc. is around $94.5, suggesting potential for significant upside from the current stock price.
  • Institutional interest is strong, with numerous investors adding shares to their portfolios, reflecting a positive outlook on the company's growth prospects.

Cons of Alcon

  • Recent hedge fund activity shows some significant sell-offs, with major investors reducing their positions, which could indicate a lack of confidence in the stock's short-term performance.
  • One member of Congress recently sold shares of Alcon Inc., which may raise concerns about insider sentiment regarding the company's future.
  • Despite positive analyst ratings, the stock market can be volatile, and external economic factors could negatively impact Alcon Inc.'s performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$31.39 billion
P/E Ratio
38.23
Consensus Rating
Moderate Buy
Consensus Price Target
$85.12 (+34.2% Upside)
Volume
401,029 shares
Average Volume
1.73 million shares
Today's Range
$62.49
$63.33
50-Day Range
$61.98
$87.14
52-Week Range
$61.83
$95.07
Dividend Yield
N/A
Revolution Medicines stock logo

44. Revolution Medicines NASDAQ:RVMD

$142.57 -1.58 (-1.09%)
As of 10:35 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Market Capitalization
$30.42 billion
P/E Ratio
N/A
Consensus Rating
Buy
Consensus Price Target
$103.88 (-27.1% Downside)
Volume
123,876 shares
Average Volume
3.44 million shares
Today's Range
$142.21
$144.03
50-Day Range
$92.51
$152.54
52-Week Range
$34.00
$155.70
Dividend Yield
N/A
Royalty Pharma stock logo

45. Royalty Pharma NASDAQ:RPRX

$51.78 +0.14 (+0.26%)
As of 10:35 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. More about Royalty Pharma

Pros of Royalty Pharma

  • The current stock price is around $49.56, which is near its 1-year high, indicating strong market performance and investor confidence.
  • Royalty Pharma plc has a solid annualized dividend yield of approximately 1.9%, providing a steady income stream for investors.
  • The company has received multiple upgrades from analysts, with a consensus rating of "Buy" and an average price target suggesting potential for further price appreciation.

Cons of Royalty Pharma

  • The stock has experienced a slight decline of about 0.3% recently, which may raise concerns about short-term volatility.
  • Royalty Pharma plc has a relatively high price-to-earnings (P/E) ratio, suggesting that the stock may be overvalued compared to its earnings potential.
  • The company has a debt-to-equity ratio of 0.88, indicating that it has a moderate level of debt, which could pose risks if market conditions change.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$29.82 billion
P/E Ratio
35.17
Consensus Rating
Buy
Consensus Price Target
$53.71 (+3.7% Upside)
Volume
239,439 shares
Average Volume
3.51 million shares
Today's Range
$51.35
$52.14
50-Day Range
$45.36
$51.65
52-Week Range
$32.15
$52.14
Dividend Yield
1.85%
Biogen stock logo

46. Biogen NASDAQ:BIIB

$199.92 +1.97 (+1.00%)
As of 10:35 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. More about Biogen

Pros of Biogen

  • Recent price target increases from major analysts, including Morgan Stanley and Sanford C. Bernstein, suggest a positive outlook for Biogen Inc.'s stock, with targets around $200.00 indicating potential upside from current levels.
  • The stock has shown resilience, trading around $182.67 recently, which reflects a stable market position and investor interest.
  • Biogen Inc. has received multiple "Buy" ratings from analysts, indicating strong confidence in the company's future performance and growth potential.

Cons of Biogen

  • Despite recent positive ratings, the stock has faced volatility, with a one-year high of $202.41 and a low of $115.25, indicating potential risks associated with price fluctuations.
  • Some analysts have issued "Hold" ratings, suggesting that while the stock may not be a strong buy, it also lacks strong sell signals, indicating uncertainty in its future performance.
  • Recent price target adjustments have shown a downward trend from some analysts, which may reflect concerns about the company's growth prospects in a competitive biotechnology market.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$29.61 billion
P/E Ratio
21.52
Consensus Rating
Moderate Buy
Consensus Price Target
$214.23 (+7.2% Upside)
Volume
103,573 shares
Average Volume
1.28 million shares
Today's Range
$196.47
$200.49
50-Day Range
$172.34
$197.95
52-Week Range
$119.18
$202.41
Dividend Yield
N/A
ResMed stock logo

47. ResMed NYSE:RMD

$202.72 +3.96 (+1.99%)
As of 10:35 AM Eastern
This is a fair market value price provided by Massive. Learn more.

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. More about ResMed

Pros of ResMed

  • The current stock price is around $217, which reflects a recent decline but may present a buying opportunity for investors looking for value.
  • ResMed Inc. has shown strong revenue growth, with a reported increase of approximately 11% year-over-year, indicating robust demand for its medical equipment.
  • The company maintains a solid financial position, highlighted by a low debt-to-equity ratio, suggesting it is well-managed and less risky compared to heavily leveraged companies.

Cons of ResMed

  • The stock has recently reached a 52-week low, which may indicate underlying issues or market sentiment that could affect future performance.
  • Some analysts have downgraded their ratings, reflecting concerns about the company's growth prospects in a competitive market.
  • ResMed Inc. has experienced fluctuations in stock price, which could lead to volatility and uncertainty for investors looking for stable returns.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$29.56 billion
P/E Ratio
19.57
Consensus Rating
Moderate Buy
Consensus Price Target
$286.18 (+41.2% Upside)
Volume
180,681 shares
Average Volume
1.14 million shares
Today's Range
$200.00
$202.35
50-Day Range
$198.87
$259.18
52-Week Range
$198.61
$293.81
Dividend Yield
1.16%
IQVIA stock logo

48. IQVIA NYSE:IQV

$174.14 +0.59 (+0.34%)
As of 10:35 AM Eastern
This is a fair market value price provided by Massive. Learn more.

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. More about IQVIA

Pros of IQVIA

  • The current stock price is around $178, which may present a buying opportunity for investors looking for growth in the life sciences sector.
  • IQVIA Holdings Inc. has demonstrated strong financial performance, reporting a revenue increase of over 8% compared to the same quarter last year, indicating robust demand for its services.
  • The company has a solid return on equity of 30.50%, suggesting effective management and profitability, which can be attractive to investors seeking reliable returns.

Cons of IQVIA

  • The stock has experienced volatility, with a beta of 1.18, indicating that it may be more volatile than the overall market, which could pose risks for conservative investors.
  • Despite recent revenue growth, the company has a relatively high debt-to-equity ratio of 2.20, which may raise concerns about financial stability and the ability to manage debt effectively.
  • Recent analyst price targets have been adjusted downward, with some estimates dropping significantly, which could indicate a lack of confidence in the stock's near-term performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$29.10 billion
P/E Ratio
21.61
Consensus Rating
Buy
Consensus Price Target
$225.69 (+29.6% Upside)
Volume
103,059 shares
Average Volume
1.93 million shares
Today's Range
$170.98
$174.74
50-Day Range
$156.42
$179.09
52-Week Range
$134.65
$247.04
Dividend Yield
N/A
Natera stock logo

49. Natera NASDAQ:NTRA

$203.93 +4.79 (+2.40%)
As of 10:35 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Market Capitalization
$29.01 billion
P/E Ratio
N/A
Consensus Rating
Moderate Buy
Consensus Price Target
$256.60 (+25.8% Upside)
Volume
256,384 shares
Average Volume
1.28 million shares
Today's Range
$198.01
$205.98
50-Day Range
$182.65
$219.82
52-Week Range
$131.81
$256.36
Dividend Yield
N/A
GE HealthCare Technologies stock logo

50. GE HealthCare Technologies NASDAQ:GEHC

$62.24 +0.54 (+0.88%)
As of 10:35 AM Eastern
This is a fair market value price provided by Massive. Learn more.

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. More about GE HealthCare Technologies

Pros of GE HealthCare Technologies

  • The company has a strong topline growth story, indicating potential for revenue increases, which is attractive for investors looking for growth opportunities.
  • Recent operational updates, including the combination of Imaging and Advanced Visualization Solutions into Advanced Imaging Solutions, suggest a strategic focus on enhancing execution and innovation, which could lead to improved market positioning.
  • Insider buying activity, with key executives purchasing shares at around $60.45 and $59.92, indicates confidence in the company's future performance, which can be a positive signal for investors.

Cons of GE HealthCare Technologies

  • Recent guidance cuts for FY26 EPS to a range of $4.80–5.00, below consensus estimates, indicate potential challenges in meeting market expectations, which can lead to negative sentiment among investors.
  • Margin pressure due to inflation and rising costs related to chips, oil, and freight has been cited as a concern, which could impact profitability in the near term.
  • Analyst downgrades and price-target cuts from major firms like JPMorgan and Citigroup signal lowered expectations for the company's performance, contributing to downward pressure on the stock.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$28.36 billion
P/E Ratio
14.91
Consensus Rating
Hold
Consensus Price Target
$80.67 (+29.6% Upside)
Volume
318,206 shares
Average Volume
4.11 million shares
Today's Range
$61.73
$62.48
50-Day Range
$59.49
$84.27
52-Week Range
$58.75
$89.77
Dividend Yield
0.22%